Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Uveal Melanoma 1Melanoma 1Lymphoma, Mantle-Cell 1Leukemia, Prolymphocytic 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

fludarabine phosphate 37Cyclophosphamide 26Mycophenolic Acid 23Whole-Body Irradiation 22Peripheral Blood Stem Cell Transplantation 17Cyclosporine 16fludarabine 13Tacrolimus 13Antilymphocyte Serum 13Rituximab 10Cyclosporins 10Busulfan 10Filgrastim 8Sirolimus 7Methotrexate 7Therapeutics 5Granulocyte Colony-Stimulating Factor 5Cord Blood Stem Cell Transplantation 5ibrutinib 4Melphalan 4Cytarabine 4Allopurinol 4Thiotepa 3Epoetin Alfa 3Darbepoetin alfa 3Alemtuzumab 3thymoglobulin 2pegfilgrastim 2Stem Cell Transplantation 2Radiotherapy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Leukemia, Prolymphocytic × sotrastaurin × Clear all
NCT02285244 2017-04-05

Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Prolymphocytic Leukemia, or Richter's Transformation

Ohio State University Comprehensive Cancer Center

Phase 2 Withdrawn
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡